Home/Filings/4/0001214659-22-012392
4//SEC Filing

Greenberg Richard S 4

Accession 0001214659-22-012392

CIK 0001625288other

Filed

Oct 17, 8:00 PM ET

Accepted

Oct 18, 11:07 AM ET

Size

13.4 KB

Accession

0001214659-22-012392

Insider Transaction Report

Form 4
Period: 2022-10-17
Greenberg Richard S
DirectorEVP and Chairman10% Owner
Transactions
  • Award

    Common Stock

    2022-10-17+250,0005,185,193 total
Holdings
  • Class C Warrant

    Exercise: $0.05From: 2020-11-24Exp: 2025-11-24common stock (1,062,953 underlying)
    1,062,953
  • Options to purchase common stock (right to buy)

    Exercise: $0.54From: 2018-07-25Exp: 2025-07-25common stock (150,000 underlying)
    150,000
  • Class A Warrant

    Exercise: $0.04From: 2020-11-24Exp: 2025-11-24common stock (1,062,953 underlying)
    1,062,953
  • Options to purchase common stock (right to buy)

    Exercise: $0.08From: 2020-08-19Exp: 2027-08-19common stock (2,500,000 underlying)
    2,500,000
  • Options to purchase common stock (right to buy)

    Exercise: $0.66From: 2018-10-26Exp: 2025-10-26common stock (100,000 underlying)
    100,000
  • Class B Warrant

    Exercise: $0.04From: 2020-11-24Exp: 2025-11-24common stock (1,062,953 underlying)
    1,062,953
  • Convertible note

    Exercise: $0.04From: 2020-11-24Exp: 2023-11-24common stock (1,062,953 underlying)
    40,000
Footnotes (1)
  • [F1]Issued in lieu of compensation for services.

Issuer

NEXIEN BIOPHARMA, INC.

CIK 0001625288

Entity typeother

Related Parties

1
  • filerCIK 0001719461

Filing Metadata

Form type
4
Filed
Oct 17, 8:00 PM ET
Accepted
Oct 18, 11:07 AM ET
Size
13.4 KB